Compare AbbVie Inc (ABBV) vs First Citizens BancShares Inc (FCNCA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs First Citizens BancShares Inc — how do they compare? AbbVie Inc trades at $253.77 (market cap $449.91B), while First Citizens BancShares Inc trades at $2,053.5 (market cap $23.94B). The key difference: AbbVie Inc is far larger — about 18.8× First Citizens BancShares Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | FCNCA | |
|---|---|---|
Market Cap | $449.91B | $23.94B |
Sector | Health | Sector/Thematic |
52-Week High | $261.07 | $2.20K |
52-Week Low | $184.85 | $1.64K |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
First Citizens BancShares (FCNCA) trades at $2,117.35, up 1.65% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamental health with a P/E of 12.21 and net income margin of 24.35%, supported by consecutive earnings beats including Q1 2026 EPS of $44.86 versus $39.56 expected. Recent corporate developments include the planned rebranding of Silicon Valley Bank and expansion of commercial banking capabilities.
The outlook remains positive given earnings momentum and analyst consensus price target of $2,320, though risks include margin pressure and credit exposure from the SVB integration. Upside potential hinges on continued execution amid a competitive banking landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →
